NEW YORK (Thomson Financial) - Warner Chilcott Ltd. Monday said it received
approval from the Food and Drug Administration for its 150 milligram strength
Doryx delayed-release tablets.
The tablets are used to treat severe acne. The company already sells Doryx
in 75 milligram and 100 milligram strengths.
Shares of Warner Chilcott closed Friday at $17.15.
Ryan Vlastelica
rv/vj
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|